Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
October 27, 2022 at 08:16 am EDT
Share
Alnylam Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 264.31 million compared to USD 187.63 million a year ago. Net loss was USD 405.92 million compared to USD 204.51 million a year ago. Basic loss per share from continuing operations was USD 3.32 compared to USD 1.72 a year ago. Diluted loss per share from continuing operations was USD 3.32 compared to USD 1.72 a year ago.
For the nine months, revenue was USD 702.38 million compared to USD 585.75 million a year ago. Net loss was USD 923.66 million compared to USD 594.36 million a year ago. Basic loss per share from continuing operations was USD 7.62 compared to USD 5.04 a year ago. Diluted loss per share from continuing operations was USD 7.62 compared to USD 5.04 a year ago.
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
ALNYLAM PHARMACEUTICALS, INC. 
